

Research and Reviews: Journal of Pharmaceutics and Nanotechnology

Fast Dissolving Drug Delivery System: A Review

Spandana Peddinti*

B pharmacy, St. Anns college of Pharmacy, Vizianagaram, Andhra Pradesh, India

Review Article

Received: 03/05/2016
Accepted: 15/06/2016
Published: 23/06/2016

*For Correspondence

Spandana Peddinti, B pharmacy,
St. Anns college of Pharmacy,
Vizianagaram, Andhra Pradesh,
Tel: 7382103469

E-Mail:

spandanapeddinti@gmail.com

Keywords:

Telmisartan;
Disintegration; Dissolution;
Bioavailability.

ABSTRACT

Oral courses of medication organization have wide acknowledgment up to 50-60% of aggregate measurement shapes. Strong measurements structures are well known in view of simplicity of administration, exact dose, self-prescription, and pain avoidance and most importantly the patient compliance. The most prevalent solid dosage forms are being tablets and capsules; one imperative downside of this dose shapes for a few patients, is the trouble to swallow. Drinking water plays a vital part in the swallowing of oral dosage forms.

INTRODUCTION

A few people experience inconvenience in swallowing conventional dosage forms such as tablet when water is not available, in the case of the motion sickness (kinetosis) and sudden episodes of coughing during the common cold, hypersensitive condition and bronchitis [1-10]. For these reasons, tablets that can quickly break up or disintegrate in the oral cavity have pulled in a lot of consideration. Dispersible tablets are not only indicated for people who have swallowing difficulties, but also are ideal for active people [11-25]. Fast dissolving tablets are additionally called as mouth-dissolving tablets, melt-in mouth tablets, Orodispersible tablets, rapimelts, permeable tablets, speedy dissolving and so on. Fast dissolving tablets are those when put on tongue break down immediately discharging the medication which disintegrate or scatters in the salivation. A few medications are consumed from the mouth, pharynx and throat as the salivation goes down into the stomach. In such cases, bioavailability of medication is altogether more prominent than those saw from customary tablets dose structure. The benefit of mouth dissolving dose structures is progressively being perceived in both, industry and academics [25-31]. As specified by European pharmacopeia, the ODT ought to disperse/disintegrate in under three minutes. The essential methodology being developed of FDT is the utilization of superdisintegrants like cross connected carboxymethyl cellulose (croscarmellose), sodium starch glycolate (primogel, explotab), polyvinylpyrrolidone (polyplasdone) and so on, which give instantaneous disintegration of tablet in the wake of putting on tongue, there by discharge the medication in salivation [32-39]. The bioavailability of a few medications might be expanded because of assimilation of medication in oral cavity furthermore because of pregastric retention of spit containing scattered medications that go down into the stomach. All the more ever, the measure of medication that is subjected to first pass digestion system is diminished when contrasted with standard tablet. The advances utilized for assembling fast dissolving tablets are freeze-drying, spray-drying, tablet molding, sublimation, sugar-based excipients, tablet compression, and disintegration addition [40-48]. As an aftereffect of expanded future, the elderly constitute a vast segment of the overall populace today. These individuals eventually will experience deterioration of their physiological and physical capacities.

Analysis with Drug

Telmisartan is Angiotensin II Receptor Antagonist, which is utilized as a part of the counteractive action and treatment of Hypertension. Telmisartan has a place with class II drug in BCS grouping i.e. low solubility and high permeability [49-60]. One of the significant issues with this medication is its low solubility in organic liquids, which results into poor bioavailability after oral administration.

The solvency of Telmisartan in fluid medium was low i.e. 0.078 mg/ml in water. Total bioavailability of the Telmisartan was 42-58% and natural half-life is just 24 hours that outcomes into poor bioavailability after oral administration. Poor solubility of Telmisartan prompts poor disintegration and consequently variety in bioavailability [61-71]. In this way increasing fluid solvency and disintegration of Telmisartan is of therapeutic importance.

Criteria for Fast Dissolving Drug Delivery System

The fast dissolving tablets should contain the following properties

- a) No involvement water to swallow, but rather it ought to dissolve or disintegrate in the mouth in matter of seconds [71-76].
- b) Be compatible with taste masking and portable without fragility concern
- c) Have a wonderful mouth feel. Leave least or no residue in the mouth after oral organization [77-85].
- d) Show low sensitive to natural condition as temperature and humidity. Permit the manufacture of the tablet utilizing conventional processing and packaging equipments at low cost

Importance Features and Benefits of Fast Dissolving Tablets

- a) Simplicity of Administration to the patient who can't swallow, for example, the elderly, stroke casualties, laid up patients, understanding influenced by renal failures and patient who decline to swallow, for example, pediatric, geriatric and psychiatric patients [86-91].
- b) No need of water to swallow the medication, which is very advantageous feature for patients who are travelling and don't have prompt access to water. Fast disintegration and absorption of the medication, which will deliver speedy onset of activity [92-100].
- c) Valuable in cases, for example, motion sickness, sudden episodes of allergic attack or coughing, where an ultra-quick on set of activity required.

Limitations of Mouth Dissolving Tablets

- a) Tablets usually have insufficient mechanical strength. Hence, it should be handled carefully.
- b) Tablets may leave unpleasant taste, odor and/or grittiness in mouth if not formulated properly.

Techniques for Preparing Fast Dissolving Tablets

Many techniques have been reported for the formulation of Fast dissolving tablets or Orodispersible tablets. 1. Freeze drying / lyophilization 2. Tablet Moulding 3. Spray drying 4. Sublimation 5. Direct compression 6. Mass extrusion

Freeze-drying or lyophilization

Freeze drying is the procedure in which water is sublimed from the product after it is solidified. This method makes an indistinct permeable structure that can dissolve quickly. A regular methodology required in the assembling of ODT utilizing this strategy is said here. The dynamic medication is dissolved or dispersed in a aqueous solution of a carrier/polymer

Tablet molding

Molding procedure is of two sorts i.e. solvent method and heat method. Solvent technique includes moistening the powder mix with a hydro alcoholic dissolvable tool after by pressure at low weights in shaped plates to frame a wetted mass (pressure forming). The solvent is then evacuated via air-drying. The tablets produced in this way are less compact than compressed tablets and forces a permeable structure that hastens dissolution. The heat molding procedure includes arrangement of a suspension that contains a medication, agar and sugar (e.g. mannitol or lactose) and pouring the suspension in the blister packaging wells, solidifying the agar at the room temperature to form a jelly and drying at 30°C under vacuum. The mechanical quality of formed tablets involves awesome concern.

Spray drying

In this method, gelatin can be utilized as a supporting agent and as a network, mannitol as a bulking agent and sodium starch glycolate or croscarmellose or crospovidone are utilized as superdisintegrants. Tablets produced from the spray dried powder have been reported for to disintegrate in under 20 seconds in aqueous medium. The formulation contained bulking agent like mannitol and lactose, a superdisintegrant like sodium starch glycolate and croscarmellose sodium and acidic fixing (citrus extract) and/or basic fixings (e.g. sodium bicarbonate). This spray-dried powder, which compressed into tablets demonstrated quick disintegration and upgraded disintegration.

Sublimation

To create a porous matrix, volatile ingredients are consolidated in the formulation that is later subjected to a procedure of sublimation. Highly volatile ingredients like ammonium bicarbonate, ammonium carbonate, benzoic corrosive, camphor, naphthalene, urea, urethane and phthalic anhydride might be compressed alongside different excipients into a tablet. This volatile material is then evacuated by sublimation leaving behind a highly porous matrix. Tablets produced by this method have answered to ordinarily disintegrate in 10-20 sec. Indeed, even solvents like cyclohexane; benzene can be utilized as pore forming agents.

Direct compression

Direct compression represents to the least complex and most savvy tablet manufacturing procedure. This procedure can now be applied to preparation of ODT as a result of the availability of improved excipients particularly superdisintegrants and sugar based excipients.

Mass-extrusion

This innovation includes softening the dynamic mix utilizing the solvent mixture of water-solvent polyethylene glycol and methanol and consequent expulsion of softened mass through the extruder or syringe to get a cylinder of the item into even portions utilizing heated blade to form tablet. The dried cylinder can likewise be used to coat granules for bitter drugs and in this way accomplish taste concealing.

REFERENCES

1. Ikoni JO et al. Some characteristics of theophylline tablets coated with samples of grewia gum obtained from a novel extraction. *J Pharm Drug Deliv Res.* 2014;3:1.
2. Nair AK et al. Development and comparative assessment of hydrocolloid based against wax based gastro retentive bilayered floating tablet designs of atorvastatin calcium using qbd approach. *J Pharm Drug Deliv Res.* 2015;4:3.
3. Mahipalreddy D et al. Preparation and evaluation of ketoprofen enteric coated mini tablets for prevention of chronic inflammatory disease. *J Pharm Drug Deliv Res.* 2015;4:2.
4. Efentakis M and Siamidi A. Design and evaluation of a multi-layer tablet system based on dextran. *J Pharm Drug Deliv Res.* 2014;3:2.
5. Sharma B et al. Formulation, optimization and evaluation of atorvastatin calcium loaded microemulsion. *J Pharm Drug Deliv Res.* 2012;1:3.
6. Zhou Y et al. Therapeutic effects of sinomenine microemulsion-based hydrogel on adjuvant-induced arthritis in rats. *J Pharm Drug Deliv Res.* 2012;1:3.
7. Ibtehal S et al. Preparation of zaleplon microparticles using emulsion solvent diffusion technique. *J Pharm Drug Deliv Res.* 2012;1:3.
8. Saxena Brij B et al. Development of a nanoporous elastomere intra-vaginal ring (ivr) for the sustained release of non-hormonal contraceptives. *J Pharm Drug Deliv Res.* 2012;1:1.
9. Vijayarajkumar P et al. Efavirenz loaded novel citric acid dendritic architecture for increased solubility and sustained delivery. *J Pharm Drug Deliv Res.* 2012;1:1.
10. Meier-Davis SR et al. Enhancing the skin flux of tolnaftate utilizing the novel excipient, dodecyl-2-n,n-dimethylaminopropionate (DDAIP). *J Pharm Drug Deliv Res.* 2012;1:1.
11. Kipping T and Rein H. Development of extruded starch based formulations aimed for local drug delivery to oral cavity. *J Pharm Drug Deliv Res.* 2012;1:1.
12. Bruce YY. Prospect of 19F mri-guided drug delivery. *J Pharm Drug Deliv Res.* 2012;1:1.
13. Akintunde JK et al. Sub-Chronic treatment of sildernafil citrate (viagra) on some enzymatic and non-enzymatic antioxidants in testes and brain of male rats. *J Pharm Drug Deliv Res.* 2012;1:2.
14. Al-Malah KI. Prediction of aqueous solubility of organic solvents as a function of selected molecular properties. *J Pharm Drug Deliv Res.* 2012;1:2.
15. D'Cruz OJ and Uckun FM. Targeting spleen tyrosine kinase (syk) for treatment of human disease. *J Pharm Drug Deliv Res.* 2012;1:2.

16. Isabel S and Paula G. Encapsulation of fluoroquinolones in 1-palmitoyl-2-myristoyl-phosphatidylcholine: cholesterol liposomes. *J Pharm Drug Deliv Res.* 2013;2:1.
17. Satya Krishna HP, et al. Solubility and dissolution enhancement of candesartan cilexetil by liquid solid compacts. *J Pharm Drug Deliv Res.* 2013;2:2.
18. Scott D and Bae Y. Block copolymer crosslinked nanoassemblies co-entrapping hydrophobic drugs and lipophilic polymer additives. *J Pharm Drug Deliv Res.* 2013;2:2.
19. Mohamed Idrees RY and Khalid A. Comparative modeling of serotonin receptors 5ht2a and 5ht2c and in-silico investigation of their potential as off-target to ethinylestradiol. *J Pharm Drug Deliv Res.* 2013;2:2.
20. ElShaer A et al. Preparation and evaluation of amino acid based salt forms of model zwitterionic drug ciprofloxacin. *J Pharm Drug Deliv Res.* 2013;2:1.
21. Frank T. Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes. *J Pharm Drug Deliv Res.* 2013;2:1.
22. Akash MSH, et al. Characterization of ethylcellulose and hydroxypropyl methylcellulose microspheres for controlled release of flurbiprofen. *J Pharm Drug Deliv Res.* 2013;2:1.
23. Dey B et al. Comparative evaluation of hypoglycemic potentials of eucalyptus spp. leaf extracts and their encapsulations for controlled delivery. *J Pharm Drug Deliv Res.* 2014;3:2.
24. Humayoon R et al. Quality control testing and equivalence of doxycycline hyclate (100 mg) capsule brands under biowaiver conditions. *J Pharm Drug Deliv Res.* 2014;3:2.
25. Ranjna CD et al. Inhibiting human lactate dehydrogenase-c for male fertility control; initial hits. *J Pharm Drug Deliv Res.* 2014 3:2.
26. Brijesh KV et al. Physicochemical characterization and in-vitro dissolution enhancement of bicalutamide-hp- β -cd complex. *J Pharm Drug Deliv Res.* 2015;3:2.
27. Gunjan J and Swarnlata S. Topical delivery of curcuma longa extract loaded nanosized ethosomes to combat facial wrinkles. *J Pharm Drug Deliv Res.* 2014;3:1.
28. Chopra AK et al. Box-Behnken designed fluconazole loaded chitosan nanoparticles for ocular delivery. *J Pharm Drug Deliv Res.* 2014;3:1.
29. Ferreira H et al. Deformable liposomes for the transdermal delivery of piroxicam. *J Pharm Drug Deliv Res.* 2015;4:4.
30. Solomon AO, et al. Making drugs safer: improving drug delivery and reducing side-effect of drugs on the human biochemical system. *J Pharm Drug Deliv Res.* 2015;4:4.
31. Orji JI et al. Physicochemical properties of co-precipitate of plantain peel cellulose and gelatin. *J Pharm Drug Deliv Res.* 2015;4:4.
32. Parteni O et al. The release of tacrolimus from a cotton biomaterial to dermis. *J Pharm Drug Deliv Res.* 2016;5:1.
33. Strehlow B et al. A novel microparticulate formulation with allicin in situ synthesis. *J Pharm Drug Deliv Res.* 2016;5:1.
34. Abdou EM and Ahmed NM. Terconazole proniosomal gels: effect of different formulation factors, physicochemical and microbiological evaluation. *J Pharm Drug Deliv Res.* 2016;5:1.
35. Adesina SK et al. Nanoparticle characteristics affecting efficacy. *J Pharm Drug Deliv Res.* 2016;5:1.
36. Bassani AS et al. In vitro characterization of the percutaneous absorption of lorazepam into human cadaver torso skin, using the franz skin finite dose model. *J Pharm Drug Deliv Res.* 2015;4:2.
37. Lokesh BVS and Kumar PV. Enhanced cytotoxic effect of chemically conjugated polymeric sirolimus against ht-29 colon cancer and a-549 lung cancer cell lines. *J Pharm Drug Deliv Res.* 2015;4:2.
38. Satyavathi K et al. Formulation and in-vitro evaluation of liposomal drug delivery system of cabazitaxel. *J Pharm Drug Deliv Res.* 2015;4:2.
39. Radu CD et al. Comparative study of a drug release from a textile to skin. *J Pharm Drug Deliv Res.* 2015;4:2.
40. Balekari U and Veeresham C. Insulinotropic agents from medicinal plants. *J Pharm Sci Emerg Drugs.* 2014;2:1.
41. Rana VS. Separation and identification of swertiamarin from *enicostema axillare lam. raynal* by centrifugal partition chromatography and nuclear magnetic resonance-mass spectrometry*. *J Pharm Sci Emerg Drugs.* 2015;2:1.
42. Resende GOD et al. First dose combination studies of anti-tuberculosis drugs with piperic acid. *J Pharm Sci Emerg Drugs.* 2014;2:1.
43. Chiririwa H. Synthesis, characterization of gold (iii) complexes and an in vitro evaluation of their cytotoxic properties. *J Pharm Sci Emerg Drugs.* 2014;2:1.
44. Naik DR et al. Release kinetics of cellulosic nano particulate formulation for oral administration of an antiviral drug: effect of process and formulation variables. *J Pharm Sci Emerg Drugs.* 2014;2:1.
45. Koly SF et al. An in vitro study of binding of aceclofenac and pantoprazole with bovisne serum albumin by uv spectroscopic method. *J Pharm Sci Emerg Drugs.* 2016;4:1.
46. Kogawa AC et al. Characterization of darunavir: β -cyclodextrin complex and comparison with the forms of darunavir ethanolate and hydrate. *J Pharm Sci Emerg Drugs.* 2016;4:1.
47. Chaube R et al. Pentachlorophenol-induced oocyte maturation in catfish heteropneustes fossils: an in vitro study correlating with changes in steroid profiles. *J Pharm Sci Emerg Drugs.* 2016;4:1.
48. Pardhi D et al. Evaluation of the Potential of Natural Biodegradable Polymers (*Echinochloa Colonom Starch*) and its Derivatives in Aqueous Coating of Hydrophilic Drugs. *J Pharm Sci Emerg Drugs.* 2016;4:1.

49. Patel MN et al. Synthesis, characterization and biological elucidation of mixed ligand cu(ii) complexes as artificial metallonucleases. *J Pharm Sci Emerg Drugs*. 2015;3:1.
50. Tsompos C et al. The effect of the antioxidant drug “u-74389g” on uterus inflammation during ischemia reperfusion injury in rats. *J Pharm Sci Emerg Drugs*. 2015;3:1.
51. Swapnil S et al. Healing potential of citrullus lanatus in acetic acid induced ulcerated rats. *J Pharm Sci Emerg Drugs*. 2015;3:1.
52. Lopes CM. Therapeutics delivery: innovations technology approaches. *Lopes, Drug Des*. 2014;3:e123.
53. Chow SC. On assessment of analytical similarity in biosimilar studies. *Drug Des*. 2014;3:e124.
54. Lu Q et al. On two-stage adaptive seamless design with count data from different study durations under weibull distribution. *Drug Des*. 2014;3:114.
55. Sherkhane AS and Gomase VS. Identification of binding affinity of tap peptides for development of fragment based vaccine from long neurotoxin 2 [N. naja]. *Drug Des*. 2014;3:115.
56. Toshihiko T. Multifunctionality of drug's pharmacophores within an organism. *Drug Des*. 2014;3:116.
57. Bielecka AM and Obuchowicz E. Chronic physiological hypoxia and high glucose concentration promote resistance of t98g glioblastoma cell line to temozolomide. *Drug Des*. 2014;3:117.
58. Stoicescu M and Bungau S. Contraceptive pills consumption risk factor of the breast cancer original case report. *Drug Des*. 2014;3:118.
59. Lopes CM and Soares C. Transdermal drug delivery systems activated by physical stimuli: techniques and applications. *Drug Des*. 2015;4:e129.
60. El-Bastawissy EA and Elhasab MA. Molecular docking and molecular dynamic simulation: insight into the difference in binding of hcv ns3/4a macrocyclic inhibitors to genotypes 1b and 4a. *Drug Des*. 2015;4:124.
61. Fang J. Reliability of machine learning based algorithms for designing protein drugs with enhanced stability. *Drug Des*. 2015;4:e130.
62. Tutar L et al. Structure Based Drug Design for Heat Shock Proteins. *Drug Des* 2016;5:e130.
63. Ceron-Carrasco JP et al. Application of computational drug discovery techniques for designing new drugs against zika virus. *Drug Des*. 2016;5:e131.
64. Gopi S et al. Effective drug delivery system of biopolymers based on nanomaterials and hydrogels - a review. *Drug Des*. 2016;5:129.
65. Ogikubo Y and Akitsu T. Enhancing medical or biological functions of laccase by cyanide-bridged cu(ii)-fe(iii) bimetallic complexes mediators. *Drug Des*. 2016;5:130.
66. Kahouli I et al. Characterization of L. reuteri NCIMB 701359 probiotic features for potential use as a colorectal cancer biotherapeutic by identifying fatty acid profile and anti-proliferative action against colorectal cancer cells. *Drug Des*. 2016;5:131.
67. Chow SC and Song F. Reproducible clinical research. *Drug Des*. 2016;5:132.
68. Vaz RJ. Fingerprints, facial recognition and cancer. *Drug Des*. 2016;5:133.
69. Damodar R et al. Formulation and evaluation of fast dissolving tablets of diclofenac sodium by novel hole technology. *J Mol Pharm Org Process Res*. 2014;2:116.
70. Madhavi K et al. Preparation, optimization and characterization of eudragit coated chitosan piroxicam microspheres intended for the treatment of rheumatoid arthritis. *Pharm Anal Acta*. 2016;7:485.
71. Samanta A et al. Formulation of catechin hydrate nanocapsule and study of its bioavailability. *Med chem (Los Angeles)*. 2016;6: 399-404.
72. Montasser MS et al. A novel eco-friendly method of using red algae (laurencia papillosa) to synthesize gold nanoprisms. *J Nanomed Nanotechnol*. 2016;7:383.
73. Israel LL et al. Ultrasound-mediated surface engineering of theranostic magnetic nanoparticles: an effective one-pot functionalization process using mixed polymers for sirna delivery. *J Nanomed Nanotechnol*. 2016;7:385.
74. Ricci JW et al. ABCG2 inhibitors: will they find clinical relevance?. *J Develop Drugs*. 2015;4:138.
75. Cuevas P et al. Efficacy of dobesilate in allergic rhinitis - case report. *J Develop Drugs*. 2015;4:139.
76. Dai Y and Zhong Z. The antioxidant activities of c3, 6-dibenzoylated phenyl-thiosemicarbazone-chitosans. *J Develop Drugs*. 2015;4:140.
77. Omidian A et al. Routes of opioid abuse and its novel deterrent formulations. *J Develop Drugs*. 2015;4:141.
78. Umar A et al. In vitro anti- acetylcholinesterase activity of crude fruits sap extract of solanum incanum in green peach aphids. *J Develop Drugs*. 2015;4:142.
79. Durišová M. Mathematical models of the pharmacokinetic behavior of digoxin in five healthy subjects following rapid intravenous injection of 1 mg of digoxin. *J Develop Drugs*. 2015;4:143.
80. Hamza AA et al. α -Glucosidase inhibitory activity of common traditional medicinal plants used for diabetes mellitus. *J Develop Drugs*. 2015;4:144.
81. Deepak Gupta et al. Nanoparticles for superior pharmacokinetics and enhanced efficacy. *J Develop Drugs*. 2015;3:e137.
82. Robak T. Approval for novel drugs in chronic lymphocytic leukemia. *J Develop Drugs*. 2014;3:e138.
83. Omidian A et al. Reported methods of abuse for common prescription analgesic opioids. *J Develop Drugs*. 2014;3:120.

84. Malika V et al. Nano-Carrier for accentuated transdermal drug delivery. *J Develop Drugs*. 2014;3:121.
85. Gestal MC and Escalante S. New initiative in ecuador, the creation of a national reference laboratory for antibiotic resistance. *J Develop Drugs*. 2014;3:122.
86. Sarkar S et al. Differential electrostatic interactions between granular species in a simple hopper chute geometry. *J Develop Drugs*. 2014;3:123.
87. Joachim Müller et al. Escherichia coli are susceptible to thiazolidines if the tolC efflux system is inhibited. *J Develop Drugs*. 2014;3:124.
88. Matsumoto S et al. In vitro synergistic effects of anthracycline antitumor agents and fluconazole against azole-resistant candida albicans clinical isolates. *J Develop Drugs*. 2014;3:125.
89. Carvalho LP et al. Anti-Parasite effects of new thiosemicarbazones and their products thiazolidinone including cellular aspects of intracellular elimination of trypanosoma cruzi in vitro. *J Develop Drugs*. 2014;3:126.
90. Kanwar SS et al. Personalized medicine through circulating tumor cells: the new dimension in cancer research. *J Develop Drugs*. 2013;2:e128
91. Vaidya A. Drug designing and development: emerging role of health technology assessment. *Drug Des*. 2014;3:111.
92. Chow SC and Pong A. Statistical designs for pharmaceutical/clinical development. *Drug Des*. 2014;3:112.
93. Jokanovic V. The deep scientific and philosophic approach to the future nanomedicine, given on the base of author introduction in the monograph "nanomedicine, the greatest challenge of the 21st century". *Drug Des*. 2014;3:113.
94. Gomase VS and Chitlange NR. Sensitive quantitative predictions of mhc binding peptides and fragment based peptide vaccines from trichinella spiralis. *Drug Des*. 2014;1:101.
95. den Haan H et al. Application of modern drug discovery techniques in the context of diabetes mellitus and atherosclerosis. *Drug Des*. 2015;4:e125.
96. Gomase VS and Kale KV. Information of surface accessibility of the peptide fragments of coat protein from alfalfa mosaic virus (amv) at the physicochemical and immunochemical levels. *Drug Des*. 2015;4:119.
97. Yuh-Jenn Wu et al. Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials. *Drug Des*. 2015;4:120.
98. Bule MH et al. Synthesis and in-vivo pharmacological evaluation of some novel 4(3h)-quinazolinone derivatives as potential anti-malarial agents. *Drug Des*. 2015;4:121.
99. Soave C et al. Repositioning an old anti-alcoholism drug: disulfiram as a selective, effective and economical anticancer agent. *J Develop Drugs*. 2016;5:e147.
100. Sreelakshmy V et al. Green synthesis of silver nanoparticles from glycyrrhiza glabra root extract for the treatment of gastric ulcer. *J Develop Drugs*. 2016;5:152.